Tuba USTAOĞLU, Nilüfer TEK, Abdullah Emre YILDIRIM

İrritabl Bağırsak Sendromunda (İBS) FODMAP Diyetinin İBS Semptomları, Beslenme Durumu ve Yaşam Kalitesi Üzerine Etkilerinin Değerlendirilmesi

Amaç: İrritabl bağırsak sendromu olan kadınlarda düşük FODMAP diyet tedavisinin (fermente oligosakkarit, disakkarit, monosakkarit ve polioller) İBS semptomlarına ve yaşam kalitesi üzerine etkilerinin değerlendirilmesidir. Bireyler ve Yöntem: Çalışma, 26 kadın İBS hastası (20-49 yaş) üzerinde yürütülmüştür. Bireyler 6 hafta boyunca düşük FODMAP diyeti uygulamıştır. Çalışma başlangıcında üç günlük besin tüketim kaydı alınmış ve çalışma sonuna kadar her hafta üçer günlük besin tüketim kaydı (her birey için 21 gün) alınarak takip edilmiştir. Bireylere İBS Semptom Şiddet Skoru (İBS-SSS), İBS Yaşam Kalitesi Ölçeği (İBS-YK) ve Hastane Anksiyete ve Depresyon Skalası (HADS) uygulanmıştır.Bulgular: Bireylerin ortalama yaşı 33.1±8.8 yıldır. Günlük FODMAP (laktoz, oligosakkaritler, mannitol ve sorbitol) alım miktarı müdahale sonrasında anlamlı olarak azalmıştır (müdahale öncesi: 13.7±7.98 g, çalışma sonu: 6.7±2.56 g; p

Evaluation of the Effects of FODMAP Diet on Irritable Bowel Syndrome Symptoms, Nutritional Status and Quality of Life

Aim: The aim of this study was to evaluate the effects of low FODMAP diet therapy (fermented oligosaccharide, disaccharide, monosaccharide and polyols) on IBS symptoms and quality of life in women with irritable bowel syndrome (IBS). Subjects and Method: The study was conducted on 26 female IBS patients (20-49 years). Individuals followed a low FODMAP diet for 6 weeks. Three-day food consumption records were taken at the beginning of the study and each week until the study ends (21 days for each individual). IBS Symptom Severity Score (IBS-SSS), IBS Quality of Life Scale (IBS-QOL), and Hospital Anxiety and Depression Scale (HADS) were administered. Results: The mean age was 33.1±8.8 years. Mean daily intake of FODMAP (lactose, oligosaccharides, mannitol and sorbitol) significantly decreased after intervention compared to baseline (at baseline: 13.7±7.98 grams, at the end of study: 6.7±2.56 grams, respectively; p

PDF

___

1. Güray Can BY. İrritabl barsak sendromunun tanı ve tedavisinde yaklaşımlar. Güncel Gastroentroloji. 2015;19(3):172-81.
2. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712-21.
3. Özden A, Köksal AŞ, Oğuz D, Çiçek B, Yilmaz U, Dağli Ü, ve ark. Türkiye’de birinci basamak sağlık kurumlarında irritabl barsak sendromu görülme sıklığı. Akademik Gastroenteroloji Dergisi. 2006;5(1):4-15
4. Kasap E, Semiz HS, Gerçeker E, Yüceyar H. İrritabl barsak sendromu ve kolonoskopi. Endoskopi Gastrointestinal. 2011;19(2):43-6.
5. Schmulson MJ, Drossman DA. What is new in Rome IV. J Neurogastroentrol Motil. 2017;23(2):151-63.
6. Soares RL. Irritable bowel syndrome: a clinical review. World J Gastroenterol. 2014;20(34):12144-60.
7. Thomas A, Quigley EM. Diet and irritable bowel syndrome. Curr Opinion Gastroenterol. 2015;31(2):166- 71.
8. Simren M, Mansson A, Langkilde AM, Svedlund J, Abrahamsson H, Bengtsson U, et al. Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion. 2001;63(2):108-15.
9. Cuomo R, Andreozzi P, Zito FP, Passananti V, De Carlo G, Sarnelli G. Irritable bowel syndrome and food interaction. World J Gastroenterol. 2014;20(27):8837-45.
10. Barrett JS, Gibson PR. Clinical ramifications of malabsorption of fructose and other short-chain carbohydrates. Practical Gastroenterology. 2007;31(8):51-65.
11. Barrett JS. Extending our knowledge of fermentable, short-chain carbohydrates for managing gastrointestinal symptoms. Nutr Clin Pract.2013;28(3):300-6.
12. Nanayakkara WS, Skidmore PM, O’Brien L, Wilkinson TJ, Gearry RB. Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date. Clin Exp Gastroenterol. 2016;9:131-42.
13. Gibson PR. Food intolerance in functional bowel disorders. J Gastroenterol Hepatol. 2011;26(3):128-31.
14. Spencer M, Chey WD, Eswaran S. Dietary renaissance in IBS: has food replaced medications as a primary treatment strategy? Curr Treat Options Gastroenterol. 2014;12(4):424-40.
15. Eswaran S, Farida JP, Green J, Miller JD, Chey WD. Nutrition in the management of gastrointestinal diseases and disorders: The evidence for the low fodmap diet. Curr Opin Pharmacol 2017;37:151-7.
16. Shepherd SJ, Gibson PR. Fructose malabsorption and symptoms of irritable bowel syndrome: guidelines for effective dietary management. J Am Diet Assoc. 2006;106(10):1631-9.
17. Staudacher HM, Whelan K, Irving PM, Lomer MC. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutr Diet. 2011;24(5):487-95.
18. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395-402.
19. Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci. 1998;43:400-11.
20. Uran B, Karadakovan A, Vardar R, Bor S. Psychometric properties of the Irritable Bowel Syndrome Quality of Life Scale in Turkey. J Hepatol Gastroint Dis. 2016;2(3):1- 7.
21. Zigmond AS, Snaith PR. The Hospital Anxiety and Depresion Scale. Acta Psychiatr Scand.1983;67:361-70.
22. Aydemir Ö. Hastane Anksiyete ve Depresyon Ölçeği Türkçe Formunun Geçerlilik ve Güvenilirlik Çalısması. Türk Psikiyatri Dergisi. 1997;8(4):49-59.
23. Yilmaz S, Dursun M, Ertem M, Canoruc F, Turhanoglu A. The epidemiological aspects of irritable bowel syndrome in Southeastern Anatolia: a stratified randomised community-based study. Int J Clin Pract. 2005;59(3):361- 9.
24. Celebi S, Acik Y, Deveci SE, Bahcecioglu IH, Ayar A, Demir A, et al. Epidemiological features of irritable bowel syndrome in a Turkish urban society. J Gastroenterol Hepatol. 2004;19(7):738-43.
25. Bohn L, Storsrud S, Liljebo T, Collin L, Lindfors P, Tornblom H, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015;149(6):1399-407.
26. Eswaran S, Dolan RD, Ball SC, Jackson K, Chey W. The Impact of a 4-week low-FODMAP and mNICE Diet on nutrient intake in a sample of US adults with irritable bowel syndrome with diarrhea. J Acad Nutr Diet. 2019; pii:S2212-2672(18) 31544-2
27. Erdinç AŞ. Konstipasyon baskın İrritabl Bağırsak Sendromu olan hastaların semptomatik tedavisinde farklı diyet türlerinin etkisi [Bilim Uzmanlığı Tezi]. Hacettepe Üniversitesi/Sağlık Bilimleri Enstitüsü, Ankara; 2018.
28. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67-75.
29. Staudacher HM. Nutritional, microbiological and psychosocial implications of the low FODMAP diet. J Gastroenterol Hepatol. 2017;32(1):16-9.
30. McIntosh K, Reed DE, Schneider T, Dang F, Keshteli AH, De Palma G, et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut. 2017;66(7):1241-51.
31. Pedersen N, Andersen NN, Végh Z, Jensen L, Ankersen DV, Felding M, et al. Ehealth: low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome. World J Gastroenterol. 2014;20(43):16215-26.
32. Michalsen VL, Vandvik PO, Farup PG. Predictors of health-related quality of life in patients with irritable bowel syndrome. A cross-sectional study in Norway. Health Qual Life Outcomes. 2015;13(1):113-22.